CN104306885A - Buccal tablets with main drug components of VE, VC and curcumin - Google Patents
Buccal tablets with main drug components of VE, VC and curcumin Download PDFInfo
- Publication number
- CN104306885A CN104306885A CN201410574630.XA CN201410574630A CN104306885A CN 104306885 A CN104306885 A CN 104306885A CN 201410574630 A CN201410574630 A CN 201410574630A CN 104306885 A CN104306885 A CN 104306885A
- Authority
- CN
- China
- Prior art keywords
- curcumin
- scheme
- buccal tablet
- buccal tablets
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 129
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 64
- 229940109262 curcumin Drugs 0.000 title claims abstract description 64
- 239000004148 curcumin Substances 0.000 title claims abstract description 64
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 58
- 239000003814 drug Substances 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 19
- 229940046011 buccal tablet Drugs 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 26
- 239000012467 final product Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 230000036541 health Effects 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 8
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 3
- 235000003373 curcuma longa Nutrition 0.000 abstract description 3
- 235000013976 turmeric Nutrition 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000003203 everyday effect Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 208000007882 Gastritis Diseases 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 208000023652 chronic gastritis Diseases 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010039966 Senile dementia Diseases 0.000 description 5
- 238000011443 conventional therapy Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000013219 diaphoresis Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000019503 curry powder Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000001060 yellow colorant Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of health products and discloses components and a preparation method of buccal tablets with main drug components of VE, VC and curcumin. The buccal tablets are prepared by tabletting active ingredients comprising 5-20 percent of curcumin, 50-85 percent of turmeric rhizome powder, 1.5-8.5 percent of VE and 5-20 percent of VC, as well as additional components comprising pharmaceutically acceptable auxiliary materials and disintegrating agents. The buccal tablets are readily available in raw materials, low in production cost, safe to eat and convenient to store, carry and take and do not have any toxic or side effect.
Description
Technical field
The invention belongs to field of health care products, be specifically related to a kind of with VE, VC and curcumin constituent that is the buccal tablet of principal agent composition and preparation method thereof.
Background technology
Rhizoma Curcumae Longae is the herbaceos perennial of Curcuma.Rhizoma Curcumae Longae is irregular oval, cylindrical or stricture of vagina capitate.The powder that Rhizoma Curcumae Longae dry rhizome grinds, as flavoring agent and yellow colorants, is the common flavouring agent that family uses, for curry powder, flavouring agent etc.Rhizoma Curcumae Longae is a kind of perennial dulcet herbaceous plant, and existing medical value, can make food seasoning again.Xin Xiang is pastel, slightly Fructus Piperis, Moschus taste and Fructus Citri sinensis and Rhizoma Zingiberis Recens mix taste, slightly pungent, bitterness.
Our said curcumin, typically refer to the mixture of curcumin, demethoxycurcumin, bisdemethoxycurcumin, curcumin is wherein most important active component.Curcumin has anti-breast cancer and carcinoma of prostate, and prevention senile dementia, blood fat reducing, promoting blood circulation to remove obstruction in the collateral, antioxidation, antiinflammatory and function of gallbladder promoting such as to protect the liver at physiology and the pharmacological action.
Modern medicine thinks that the curcumin composition in Rhizoma Curcumae Longae is slightly acid phenolic substance, has and promotes that macrophage is formed, thus improve the function of immunity of organisms.This immunocyte can remove amyloplaste (a kind of energy forms the brain plaque material be associated with senile dementia), thus reaches effect of prevention and therapy senile dementia.Now prove that curcumin has good effect to the generation of Breast Cancer Prevention and carcinoma of prostate and development; Simultaneously curcumin also have that function of gallbladder promoting protects the liver, blood fat reducing, promoting blood circulation to remove obstruction in the collateral, antioxidation, atherosclerosis and the physiology such as antiinflammatory, anti AIDS virus, pharmacological action.
Chinese always have the custom utilizing food to carry out self health care.During spring and autumn, Confucius just advocates: " often eat and do not remove Rhizoma Zingiberis Recens." meaning: people should eat Rhizoma Zingiberis Recens every day throughout the year.It is said that Confucius just has and chew several pieces custom of Rhizoma Zingiberis Recens every day after meal.Among the people have saying of " three Rhizoma Zingiberis Recens, being better than and drinking ginseng soup morning " and " Rhizoma Zingiberis Recens Radix Codonopsis Cardiophyllae in October "." winter eats the Radix Raphani summer and eats Rhizoma Zingiberis Recens, and doctor Lao does not write out a prescription to also have " every day three Rhizoma Zingiberis Recens, not labor doctor prescribed prescription "." proverb such as " often eat Rhizoma Zingiberis Recens, be not afraid of hardships ".Rhizoma Zingiberis Recens in life, except being used as flavoring agent, snack food, also demonstrates local flavor and the glamour of its uniqueness in beauty treatment, health care.Rhizoma Zingiberis Recens is hot in nature, acrid in the mouth.Return spleen, stomach, the heart, lung meridian.Effect: warming middle-JIAO, recuperating depleted YANG, warming the lung to resolve fluid-retention.There are the multiple efficacies such as cold expelling diaphoresis, preventing phlegm from forming and stopping coughing, stomach function regulating, preventing or arresting vomiting.Dry rhizome has promoting the circulation of QI to relieve pain, dysmenorrhea removing blood stasis, effects such as Liao Paralysis of dispeling the wind.Rhizoma Zingiberis head enters taste, hotly by taste cold-evil, can help the yang-energy of taste with it.Commonly use and control taste sympotoms caused by cold factors, disease sees epigastric pain, vomiting is had loose bowels.In every case taste sympotoms caused by cold factors, be no matter invade in exogenous cold or YANG QI deficiency all applicable.Therefore, develop a kind of based on the buccal tablet of Rhizoma Curcumae Longae rhizome powder, necessarily have market widely, be bound to be subject to acceptance and the accreditation of consumers in general.
Vitamin E (Vitamin E), also known as tocopherol, is one of topmost fat-soluble antioxidant.Tocopherol can promote sex hormones secretion, and man's motility of sperm and quantity are increased; Woman's estrogen concentration is increased, and improve fertility, prevention of miscarriage, also can be used for preventing and treating the aspects such as male infertility, burn, cold injury, capillary hemorrhage, climacteric syndrome, beauty treatment.Recently also find that VE can suppress the lipid peroxidation in eye lens to react, and makes peripheral vasodilation, improves blood circulation, pre-myopia prevention occurs and development.It can stop unsaturated fatty acid (linoleic acid, arachidonic acid, other electron pair acceptor), vitamin, hormone, enzyme etc. from Oxidative demage, can not only reduce the peroxidating of lipid and lipoprotein on cell membrane, the normal function of Cell protection.Lack VE and can cause hereditary and metabolic disease.Research in the last few years finds, VE has and acts on widely in control cardiovascular and cerebrovascular disease, tumor, diabetes and other complication, central nervous system disease, locomotor disease, dermatosis etc.VE also has very strong lock aqueous, so there is again the good reputation of deep skin wetting agent.
Vitamin C is water soluble antioxidant, and its effect has the biosynthesis 1. promoting ossein, is beneficial to healing sooner of tissue injury mouth; Promote the synthesis of collagen protein, prevent gingival hemorrhage; Promote the growth of tooth and skeleton, prevent dental bed hemorrhage, prevent arthralgia, lumbago and skelalgia.2. promote the metabolism of tyrosine and tryptophan in aminoacid, extend the human body life-span; Strengthen the human body anti-stress ability of environment and immunity to external world.3. the utilization of ferrum, calcium and folic acid is improved; Improve the metabolism of fat and lipoid particularly cholesterol, prevent cardiovascular diseases.4. prevention of arterial sclerosis.The excretion of cholesterol can be promoted, prevent cholesterol from depositing at Wall of Artery, the atheromatous plaque of deposition even can be made to dissolve.5. antioxidant action.Other antioxidant can be protected, as VA, VE, unsaturated fatty acid, prevent the injury of radical pair human body.In addition, VC also has certain face-nursing function.VC can suppress the increase of pigment, makes freckle thin out, has whitening effect, can reduce pore, increases the effect of collagen protein, adjustment skin texture.
The effect of curcumin is wide, good effect.Be typical functional dietetic therapy product, but have certain seasonality because China produces Rhizoma Zingiberis Recens, store difficulty comparatively large, edible process is too complicated, is not easy to long-term, regular or takes at any time, therefore, have impact on its marketability.
At present, mostly the turmeric powder that can buy of market and the health promoting product containing curcumin are imported product.Product category is enriched, and have curcumin capsule, tablet, tea and drinks, primary efficacy is hepatoprotective effect.But because the solubization of turmeric powder and curcumin and extract thereof is poor, and the features such as easy decomposition, greatly hinder the application of curcumin in functional food and health product.The market prospect developing this series health-care products with independent intellectual property right and nutriment is fine.
China enters aging society, health care, improves quality of life and more and more becomes the requirement of people to health product and functional food.The sickness rate of senile dementia increases in China fast with the speed of annual 14%, curcumin be generally acknowledge at present to the effective native compound of prevention and therapy senile dementia.Therefore, such health product and functional food are bound to be subject to the welcome in market.
Summary of the invention
Primary and foremost purpose of the present invention is to provide a kind of based on VE, VC and curcumin, there is certain health-care effect, comprise and there is function of gallbladder promoting protect the liver, increase the effects such as immunity, skin maintenance, anticancer and resisting fatigue, and to anemofrigid cold, chronic gastritis, hyperlipidemia and wound healing have certain buccal tablet with therapeutic efficiency of assisting.There is raw material be easy to get, low production cost, have no side effect, edible safety, be convenient to features such as storing, carry and take.
The object of the present invention is to provide above-mentioned a kind of with VE, VC and curcumin constituent that is the buccal tablet of principal agent composition and preparation method thereof.
Object of the present invention is achieved through the following technical solutions:
With the buccal tablet that VE, VC and curcumin are principal agent composition, be grouped into by the one-tenth of following mass percent:
Curcumin: 5-20%, Rhizoma Curcumae Longae rhizome powder: 50-85%, VE:1.5-8.5%, VC:5-20%, add pharmaceutical adjunct, above composition tabletting.
Curcumin of the present invention and Rhizoma Curcumae Longae rhizome powder are all buied from market.
Buccal tablet provided by the invention, comprising VE, VC, curcumin and Rhizoma Curcumae Longae rhizome powder.
Buccal tablet provided by the invention, wherein also comprises the acceptable adjuvant of pharmacy.
Buccal tablet provided by the invention, comprising appropriate VE, VC, curcumin and Rhizoma Curcumae Longae rhizome powder.
Above-mentioned a kind of preparation that is the buccal tablet of principal agent composition with VE, VC and curcumin:
The buccal tablet that is principal agent composition with VE, VC and curcumin of the present invention, wherein active component is made up of VE, VC, Rhizoma Curcumae Longae rhizome powder and curcumin, and its weight proportion is curcumin: 5-20%, Rhizoma Curcumae Longae rhizome powder: 50-85%, VE:1.5-8.5%, VC:5-20%; Supplementary element has filler, flavoring agent, excipient, salty sweet regulator, pH value equilibrium modifier and disintegrating agent, above composition tabletting and get final product.
The present invention adopts and curcumin, VE and V C compositions is made buccal tablet, is in view of the effective ingredient of curcumin can play collaborative and assosting effect mutually with the biologic activity of VE and VC.VE is fat-soluble antioxidant, and VC is water miscible antioxidant, effectively can protect the effective ingredient in curcumin and Rhizoma Curcumae Longae rhizome powder both above, suppresses the aerial oxidation Decomposition of curcumin.Triple combination achieves noticeable achievement in the treatment chronic gastritis improving curcumin and blood fat reducing; And the original relieving the exterior syndrome by diaphoresis function of curcumin is further strengthened, the health-care effect of this buccal tablet is further expanded.
The present invention has the following advantages and effect relative to prior art tool:
The buccal tablet that is principal agent composition with VE, VC and curcumin of the present invention, VC is water miscible antioxidant, and VE is fat-soluble antioxidant.Both antioxidations, can available protecting curcumin, suppresses the aerial oxidation Decomposition of curcumin, effectively can suppress the volatilization of curcumin volatile oil.Add before and after VC and VE, the assay of curcumin is known, and before the content of curcumin after interpolation comparatively adds, (in every hectogram) improves 41%; The content of curcumin volatile oil improves 38%; Illustrate that VE and VC prevents the oxidation Decomposition of curcumin effectively.
The buccal tablet that is principal agent composition with VE, VC and curcumin of the present invention, the original relieving the exterior syndrome by diaphoresis function of curcumin is further strengthened, the patient of anemofrigid cold takes this buccal tablet, the course of disease can be made to shorten 38.8%, and " flu " symptom of patient obviously alleviates.
The buccal tablet that is principal agent composition with VE, VC and curcumin of the present invention, is enhanced about more than once repairing the effect in the mucomembranous defect that chronic gastritis causes; In the symptoms such as alleviation climacteric fear of cold, agitation, effect is remarkable; In blood fat reducing and cholesterol reducing, the medicine of this buccal tablet and blood fat reducing plays synergism, makes effective percentage improve 41.2%, and presents the effect effectively controlling body weight.
The present invention with the addition of flavoring agent equally in buccal tablet, makes the crowd of Reflux exophagitis, is also unlikely to the stimulation being subject to pungent, bitterness when reflux.
The present invention adds disintegrating agent in buccal tablet, and the curcumin and the Rhizoma Curcumae Longae rhizome powder that make to be insoluble in this buccal tablet water can be better water-soluble, buccal tablet can also be made to be dissolved in milk and fruit juice simultaneously, be convenient to drink, make to take form more various.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention are not limited only to this.
Embodiment 1
A kind of VE, VC and curcumin are buccal tablet constituent and the preparation method of principal agent composition:
Active component forms according to percentage by weight (0.5g/ sheet): curcumin: 5%; Rhizoma Curcumae Longae rhizome powder: 85%; VE:5%; VC:5%, above composition adds pharmaceutical adjunct and disintegrating agent, tabletting.
Embodiment 2
A kind of VE, VC and curcumin are buccal tablet constituent and the preparation method of principal agent composition:
Active component forms according to percentage by weight (0.5g/ sheet): curcumin: 20%; Rhizoma Curcumae Longae rhizome powder: 51.5%; VE:8.5%; VC:20%, above composition adds pharmaceutical adjunct and disintegrating agent, tabletting.
Embodiment 3
A kind of VE, VC and curcumin are buccal tablet constituent and the preparation method of principal agent composition:
Active component forms according to percentage by weight (0.5g/ sheet): curcumin: 15%; Rhizoma Curcumae Longae rhizome powder: 63.5%; VE:1.5%; VC:20%, above composition adds pharmaceutical adjunct, tabletting.
Embodiment 4
A kind of VE, VC and curcumin are buccal tablet constituent and the preparation method of principal agent composition:
Active component forms according to percentage by weight (0.5g/ sheet): curcumin: 10%; Rhizoma Curcumae Longae rhizome powder: 66.5%; VE:8.5%; VC:15%, above composition adds pharmaceutical adjunct, tabletting.
Embodiment 5
Buccal tablet obtained by embodiment 1-4, carry out Double-blind randomized clinical trial by the patient of anemofrigid cold, experimental program is:
(1) only conventional therapy is carried out;
(2) on the basis of (1), the buccal tablet taken obtained by embodiment 1 is increased, every day 2 times, each 2;
(3) on the basis of (1), the buccal tablet taken obtained by embodiment 2 is increased, every day 2 times, each 2;
(4) on the basis of (1), the buccal tablet taken obtained by embodiment 3 is increased, every day 2 times, each 2;
(5) on the basis of (1), the buccal tablet taken obtained by embodiment 4 is increased, every day 2 times, each 2;
Result of the test shows, scheme 2 shortens 38.6% compared with the course of disease of scheme 1; Scheme 3 shortens 38.1% compared with the course of disease of scheme 1; Scheme 4 comparatively scheme 1 shortens 39.5%; Scheme 5 shortens 39.3% compared with the course of disease of scheme 1; The above results shows the buccal tablet obtained by embodiment 1-4, and its effective percentage is close, and curative effect is substantially identical.
Embodiment 6
Buccal tablet obtained by embodiment 1-4, carry out Double-blind randomized clinical trial by the patient of anemofrigid cold, testing program is:
(1) only conventional therapy is carried out;
(2) on the basis of (1), the buccal tablet taken obtained by embodiment 1-4 is increased, every day 2 times, each 2;
(3) on the basis of (1), increase and take VC, (use amount is equal with VC in (2));
(4) on the basis of (1), increase and take curcumin; (use amount is equal with curcumin in (2));
(3) on the basis of (1), increase and take VE, (use amount is equal with VE in (2));
Result of the test is: the therapeutic effect of scheme 2 is best, and scheme 2 shortens 38.8% compared with the course of disease of scheme 1, and patients symptomatic alleviates significantly; Scheme 2 shortens 20.4% compared with the course of disease of scheme 3; Scheme 2 shortens 18.1% compared with the course of disease of scheme 4, and patients symptomatic alleviates; Scheme 2 shortens 22.2% compared with the course of disease of scheme 5.The above results shows, the buccal tablet that embodiment 1-4 is obtained, and in the process of auxiliary treatment anemofrigid cold, effective percentage is close, and curative effect is substantially identical.
Embodiment 7
Buccal tablet obtained by embodiment 1-4, carry out Double-blind randomized clinical trial by the patient of chronic gastritis, experimental program is:
(1) only conventional therapy is carried out;
(2) on the basis of (1), the buccal tablet taken obtained by embodiment 1 is increased, every day 2 times, each 2;
(3) on the basis of (1), the buccal tablet taken obtained by embodiment 2 is increased, every day 2 times, each 2;
(4) on the basis of (1), the buccal tablet taken obtained by embodiment 3 is increased, every day 2 times, each 2;
(5) on the basis of (1), the buccal tablet taken obtained by embodiment 4 is increased, every day 2 times, each 2;
Result of the test shows, scheme 2 shortens 32.6% compared with the course of disease of scheme 1; Scheme 3 shortens 32.2% compared with the course of disease of scheme 1; Scheme 4 comparatively scheme 1 shortens 31.7%; Scheme 5 shortens 31.4% compared with the course of disease of scheme 1; The above results shows the buccal tablet obtained by embodiment 1-4, and in the process of auxiliary treatment chronic gastritis, effective percentage is close, and curative effect is substantially identical.
Embodiment 8
Buccal tablet obtained by embodiment 1-4, carry out Double-blind randomized clinical trial by the patient of chronic gastritis, testing program is:
(1) only conventional therapy is carried out;
(2) on the basis of (1), the buccal tablet taken obtained by embodiment 1-4 is increased, every day 2 times, each 2;
(3) on the basis of (1), increase and take VE, (use amount is equal with VE in (2));
(4) on the basis of (1), increase and take curcumin; (use amount is equal with curcumin in (2));
(5) on the basis of (1), increase and take VC, (use amount is equal with VC in (2));
Result of the test is: the therapeutic effect of scheme 2 is best, and scheme 2 shortens 32.3% compared with the course of disease of scheme 1, and gastroscopic observation cell migration is all right, and the symptom of patient's stomach discomfort significantly alleviates.Scheme 2 shortens 8.9% compared with the course of disease of scheme 3, and patients symptomatic alleviates.Scheme 2 shortens 18.2% compared with the course of disease of scheme 4, and patients symptomatic alleviates.Scheme 2 shortens 24.2% compared with the course of disease of scheme 5, and patients symptomatic alleviates.Above-mentioned result of the test shows, the adjuvant treatment effect of buccal tablet of the present invention to chronic gastritis is remarkable.
Embodiment 9
Buccal tablet obtained by embodiment 1-4, carry out Double-blind randomized clinical trial by the patient of hyperlipidemia, experimental program is:
(1) only conventional therapy is carried out;
(2) on the basis of (1), the buccal tablet taken obtained by embodiment 1 is increased, every day 2 times, each 2;
(3) on the basis of (1), the buccal tablet taken obtained by embodiment 2 is increased, every day 2 times, each 2;
(4) on the basis of (1), the buccal tablet taken obtained by embodiment 3 is increased, every day 2 times, each 2;
(5) on the basis of (1), the buccal tablet taken obtained by embodiment 4 is increased, every day 2 times, each 2;
Result of the test shows, scheme 2 shortens 41.5% compared with the course of disease of scheme 1; Scheme 3 shortens 41.1% compared with the course of disease of scheme 1; Scheme 4 comparatively scheme 1 shortens 40.8%; Scheme 5 shortens 41.7% compared with the course of disease of scheme 1; The above results shows the buccal tablet obtained by embodiment 1-4, and in the process of auxiliary treatment hyperlipidemia, effective percentage is close, and curative effect is substantially identical.
Embodiment 10
Have the buccal tablet obtained by embodiment 1-4, carry out Double-blind randomized clinical trial by the patient of hyperlipidemia, experimental program is:
(1) medicine of conventional blood fat reducing is taken
(2) on the basis of (1), the buccal tablet obtained by embodiment 1-4 is taken, every day 2 times, each 2
(3) on the basis of (1), VC is taken, (use amount is equal with VC in (2));
(4) on the basis of (1), VE is taken, (use amount is equal with VE in (2)); (5) on the basis of (1), curcumin (use amount is equal with curcumin in (2)) is taken, every day 2 times, each 2;
After six months, statistical results are: the therapeutic effect of scheme 2 is best.Scheme 2 declines 41.2% compared with the patients with lipid of scheme 1, the general status of patient, and as dizziness, spiritlessness and weakness, insomnia forgetfulness, numb limbs and tense tendons, uncomfortable in chest, the improvement of cardio palmus shape is remarkable.Scheme 2 declines 19.7% compared with the patients with lipid of scheme 3; Scheme 2 declines 25.1% compared with the patients with lipid of scheme 4; Scheme 2 declines 21.3% compared with the patients with lipid of scheme 5; Above-mentioned result of the test shows, the present invention can play synergism with the medicine of blood fat reducing.
Above-described embodiment is the better matched combined of each composition of the present invention; but embodiment of the present invention are not restricted to the described embodiments; the amendment made under other any does not deviate from spirit of the present invention and principle, substitute, combine, simplify and all should be considered as equivalent replacement mode, be included within protection scope of the present invention.
Claims (2)
1., with the compositions buccal tablet that VE, VC and curcumin are principal agent composition, it is characterized in that its active component mass percent is curcumin: 5-20%, Rhizoma Curcumae Longae rhizome powder: 50-85%, VC:5-20%, VE:1.5-8.5%; Add pharmaceutical adjunct and disintegrating agent, tabletting and get final product.
2. buccal tablet according to claim 1, is characterized in that the specification of described tablet is 0.5g/ sheet, and namely wherein the content sum of active component VE, VC, Rhizoma Curcumae Longae rhizome powder, curcumin is 0.5g/ sheet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410574630.XA CN104306885A (en) | 2014-10-24 | 2014-10-24 | Buccal tablets with main drug components of VE, VC and curcumin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410574630.XA CN104306885A (en) | 2014-10-24 | 2014-10-24 | Buccal tablets with main drug components of VE, VC and curcumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306885A true CN104306885A (en) | 2015-01-28 |
Family
ID=52362294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410574630.XA Pending CN104306885A (en) | 2014-10-24 | 2014-10-24 | Buccal tablets with main drug components of VE, VC and curcumin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306885A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764408A (en) * | 2012-01-18 | 2012-11-07 | 上海蓝怡科技有限公司 | Dealcoholic preparation |
| CN102771794A (en) * | 2012-07-31 | 2012-11-14 | 新疆伊犁州惠华酒业有限责任公司 | Soft capsule made of seabuckthorn oil and vitamins EC |
| CN104012972A (en) * | 2014-06-17 | 2014-09-03 | 广东奇灵制药有限公司 | Health-care capsule containing curcumin composition, and preparing method thereof |
-
2014
- 2014-10-24 CN CN201410574630.XA patent/CN104306885A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764408A (en) * | 2012-01-18 | 2012-11-07 | 上海蓝怡科技有限公司 | Dealcoholic preparation |
| CN102771794A (en) * | 2012-07-31 | 2012-11-14 | 新疆伊犁州惠华酒业有限责任公司 | Soft capsule made of seabuckthorn oil and vitamins EC |
| CN104012972A (en) * | 2014-06-17 | 2014-09-03 | 广东奇灵制药有限公司 | Health-care capsule containing curcumin composition, and preparing method thereof |
Non-Patent Citations (3)
| Title |
|---|
| HEE YOUNG JEON等: "A mixture of Curcumin, Vitamin C, and E Prolongs the antioxidant Effect to Beyond That of Rach Component Alone in Vivo", 《FOOD SCIENCE AND BIOTECHNOLOGY》 * |
| POONAM SHARMA等: "Variation in Serum Lipids & Liver Function Markers in Lindane Exposed Female Wistar Rats: Attenuating Effect of Curcumin,Vitamin C & vitamin E", 《ASIAN J. EXP. BIOL. SCI》 * |
| 郑州嘉康利SHAKLEE: "嘉康利--维C咀嚼片", 《HTTP://BLOG.SINA.COM.CN/S/BLOG_A9118A170101HDSZ.HTML 》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20170062755A (en) | Method of using the medicinal plants Eel Soup | |
| KR20160013227A (en) | Production method of young antler tea | |
| CN104839292A (en) | Nutrition and health care biscuit for stomach cold pain and preparation method | |
| CN104274780A (en) | Buccal tablets by taking vitamin C and curcumin as main drug components | |
| KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
| CN104382893A (en) | Soft capsule adopting VE, VC and curcumin as main medicine components | |
| CN101804018A (en) | Traditional Chinese medicine mask powder with chloasma removing function and preparation method thereof | |
| KR101606913B1 (en) | Health beverage manufacturing method using turmeric | |
| CN103734609B (en) | Chinese medicinal noodles with effects in enhancing cardiac and cerebral blood supply, supplying oxygen, invigorating spleen, tonifying qi, nourishing blood and reinforcing kidney | |
| CN106307506A (en) | Chinese traditional therapeutic method for diabetes | |
| CN102671058B (en) | Traditional Chinese medicine oral liquid for treatment of vomiting and preparation method thereof | |
| CN105250747A (en) | Health maintenance paste | |
| Bhowmik et al. | Zingiber officinale the herbal and traditional medicine and its therapeutically importance | |
| CN104306885A (en) | Buccal tablets with main drug components of VE, VC and curcumin | |
| CN106306355A (en) | Featured Chinese herbal medicine feed additive for mutton sheep as well as preparation method and feeding method of featured Chinese herbal medicine feed additive | |
| CN105688110A (en) | Donkey-hide gelatin oral liquid for enriching blood and nourishing faces, and production method thereof | |
| CN104382009A (en) | Health care tablets using VC and curcumin as components of main drugs | |
| CN104288121A (en) | Health soft capsule with VE (Vitamin E) and curcumin as main drug ingredients | |
| CN103815327A (en) | Radix-scrophulariae liver-lung-tonifying hot pot seasoning and preparation method thereof | |
| CN103536659A (en) | Traditional Chinese medicine for adjusting dysfunction of qi and blood as well as preparation method thereof | |
| CN102885956B (en) | A kind of sleeping Chinese medicine composition and preparation method thereof | |
| CN105687985A (en) | Psoralea corylifolia oral liquid for spleen warming and diarrhea stopping, and production method thereof | |
| CN105362910B (en) | A kind of medicine food formula for deficiency of blood constitution | |
| CN104474488A (en) | Traditional Chinese medicine medicinal liquor for dispelling cold and nourishing life and preparation method | |
| CN105214001B (en) | A kind of Chinese medicine composition for treating hypertensive patients coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150128 |